ANALYSIS OF FACTORS INFLUENCING TREATMENT OUTCOMES OF UTERINE SARCOMAS
DOI:
https://doi.org/10.15407/exp-oncology.2025.01.083Keywords:
sarcoma, disease prognosis, surgery, risk factors, treatment, long-term treatment outcomesAbstract
Background. Uterine sarcoma (US) is a rare type of tumor characterized by aggressive clinical behavior and high recurrence rate. Its histopathological heterogeneity has led to a lack of consensus regarding risk factors that could guide the selection of optimal treatment strategies for this pathology. Aim. To investigate the factors influencing treatment outcomes of US. Materials and Methods. We conducted a retrospective analysis of the treatment outcomes of 107 women diagnosed with stage I—II US from 2010 to 2023. The follow-up period ranged from 1.0 to 156.0 months. Kaplan — Meier survival curves were used for the analysis of overall survival (OS) and recurrence-free survival (RFS) rates. The correlation between the studied parameters was analyzed including relative risk (odds ratio, OR) and correlation coefficient. Results. The assessment of OR allowed us to identify the following prognostic factors with a negative impact on the 5-year OS and RFS of patients with US: differentiation grade G3, necrotic areas in tumor tissue, lymphovascular invasion, high mitotic activity (11 or more mitoses per 10 HPF), nuclear atypia 4+, negative ER and PR statuses, and high Ki-67 expression. Conclusions. Survival of patients with US depends on tumor grade, necrosis, and lymphovascular invasion of tumor tissue; mitotic activity and nuclear atypia; ER and PR statuses; and the level of Ki67 expression.
References
Hensley ML, Barrette BA, Baumann K, et al. Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas. Int J Gynecol Cancer. 2014;24(9):61-66. https://doi.org/10.1097/IGC.0000000000000261
Hosh M, Antar S, Nazzal A, Warda M, Gibreel A, Refky B. Uterine sarcoma: analysis of 13,089 cases based on sur- veillance, epidemiology, and end results database. Int J Gynecol Cancer. 2016;26(6):1098-1104.
Davydiuk SS, Kryzhanivska AE. Incidence of uterine sarcoma in Ivano-Frankivsk region. Art Medicine. 2022;4(24):33-39 (in Ukrainian).
Bulun SE. Uterine fibroids. N Engl J Med. 2013;369:1344-1355.
Bužinskienė D, Mikėnas S, Drąsutienė G, Mongirdas M. Uterine sarcoma: a clinical case and a literature review.
Acta Med Litu. 2018;25(4):206-218.
Felix AS, Cook LS, Gaudet MM, et al. The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium. Br J Cancer. 2013;108(3):727-734. https://doi.org/10.1038/bjc.2013.2
Meredith RF, Eisert DR, Kaka Z, et al. An excess of uterine sarcomas after pelvic irradiation. Cancer. 1986;58(9):2003- 2007. https://doi.org/10.1002/1097-0142(19861101)58:9<2003::aid-cncr2820580908>3.0.co;2-2
Robinson E, Neugut AI, Wylie P. Clinical aspects of postirradiation sarcomas. J Natl Cancer Inst. 1988;80(4):233-240.
Ganjoo KN. Uterine sarcomas. Curr Probl Cancer. 2019;43(4):283-288. https://doi.org/10.1016/j.currprob- lcancer.2019.06.001
George S, Serrano C, Hensley ML, Ray-Coquard I. Soft tissue and uterine leiomyosarcoma. J Clin Oncol. 2018;36(2):144-150. https://doi.org/10.1200/JCO.2017.75.9845
Choi J, Manzano A, Dong W, et al. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proc Natl Acad Sci U S A. 2021;118(15):2025182118. https://doi.org/10.1073/pnas.202518211
Francis M, Dennis NL, Hirschowitz L, et al. Incidence and survival of gynecologic sarcomas in England. Int J Gy- necol Cancer. 2015;25(5):850-857.
Mas A, Nair S, Laknaur A, et al. Stro-1/CD44 as putative human myometrial and fibroid stem cell markers. Fertil Steril. 2015;104:225-234. https://doi.org/10.1016/j.fertnstert.2015.04.021
Ono M, Qiang W, Serna VA, et al. Role of stem cells in human uterine leiomyoma growth. PLoS ONE. 2012;7:36935. https://doi.org/10.1371/journal.pone.0036935
Yang Q, Ali M, Bariani MV, Vafaei S, Al-Hendy A. Endocrine-disrupting chemicals and epigenetic reprogram- ming in developmental origin of uterine fibroids. Sci Prog. 2023;106:368504231215601. https://doi.org/10.1177/ 00368504231215601
Yang Q, Ali M, Treviño LS, et al. Developmental reprogramming of myometrial stem cells by endocrine disruptor linking to risk of uterine fibroids. Cell Mol Life Sci. 2023;80:274. https://doi.org/10.1007/s00018-023-04919-0
Chiang S, Samore W, Zhang L, et al. PGR gene fusions identify a molecular subset of uterine epithelioid leiomyosarco- ma with rhabdoid features. Am J Surg Pathol. 2019;43(6):810-818. https://doi.org/10.1097/PAS.0000000000001239
Parra-Herran C, Howitt BE. Uterine mesenchymal tumors: update on classification, staging, and molecular fea- tures. Surg Pathol Clin. 2019;12(2):363-396. https://doi.org/10.1016/j.path.2019.01.004
Dinh P. Hormonal therapy in uterine sarcomas. Gynecol Oncol. 2009;113(3):384-387.
Pérez-Fidalgo JA, Ortega E, Ponce J, et al. Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS). Ther Adv Med Oncol. 2023;15:17588359231157645. https://doi.org/10.1177/17588359231157645
Chiang S, Lee CH, Stewart CJR, et al. BCOR is a robust diagnostic immunohistochemical marker of genetically diverse high-grade endometrial stromal sarcoma, including tumors exhibiting variant morphology. Mod Pathol. 2017;30(9):1251-1261. https://doi.org/10.1038/modpathol.2017.42
Lewis N, Soslow RA, Delair DF, et al. ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity. Mod Pathol. 2018;31(4):674-684. https://doi.org/10.1038/modpathol.2017.162
Mariño-Enriquez A, Lauria A, Przybyl J, et al. BCOR internal tandem duplication in high-grade uterine sarcomas.
Am J Surg Pathol. 2018;42(3):335-341. https://doi.org/10.1097/PAS.0000000000000993
Yoon JY, Mariño-Enriquez A, Stickle N, et al. Myxoid smooth muscle neoplasia of the uterus: comprehensive analy- sis by next-generation sequencing and nucleic acid hybridization. Mod Pathol. 2019;32(11):1688-1697. https://doi. org/10.1038/s41379-019-0299-4
D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116(1):131-139. https://doi.org/10.1016/j.ygy- no.2009.09.02
Pan M, Ganjoo K, Karam A. Rapid response of a BRCA2/TP53/PTEN-deleted metastatic uterine leiomyosarcoma to olaparib: a case report. Perm J. 2021;25:20.251. https://doi.org/10.7812/TPP/20.251
Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncol- ogy Group study. Cancer. 1993;71(4):1702-1709.
Davyduk SS, Kryzhanivska AE. Treatment outcomes of patients with stage I uterine sarcoma. Clin Oncol. 2024;14(2):1-5. https://doi.org/10.32471/clinicaloncology.2663-466X.54-2.32539
Tropé CG, Abeler VM, Kristensen GB. Diagnosis and treatment of sarcoma of the uterus. A review. Acta Oncol. 2012;51(6):694-705. https://doi.org/10.3109/0284186X.2012.689111
Desar IM, Ottevanger PB, Benson C, Van der Graaf WT. Systemic treatment in adult uterine sarcomas. Crit Rev Oncol Hematol. 2018;1(122):10-20. https://doi.org/10.1016/j.critrevonc.2017.12.009
Giuntoli RL, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003;89:460-469. https:// doi.org/10.1016/s0090-8258(03)00137-9
D’Angelo E, Espinosa I, Ali R, et al. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. Gynecol Oncol. 2011;121(2):328-333. https://doi.org/10.1016/j. ygyno.2011.01.022.
Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004;2:256- 266. https://doi.org/10.1016/j.ygyno.2004.03.048
Jo VY, Fletcher CD. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology. 2014;46(2):95-104. https://doi.org/10.1097/PAT.0000000000000050
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
